18 October 2017 - In 2010, Josh Feldman was on his honeymoon -- a globe-spanning trip that at one point involved swimming with humpback whales -- when he noticed a "Garbanzo-sized" lump on the back of his neck. 

It turned out to be lymphoma, which worsened even as he cycled through treatments: chemotherapy, the immunotherapy Opdivo, a targeted drug called Zydelig. What actually worked for the 55-year-0ld photographer was a radical treatment in which his own white blood cells were genetically re-engineered to kill his cancer. Compared to the other drugs, it was "a walk in the park," he said earlier this year while overlooking a mango tree on his property. "I'd like to see it become first-line therapy," he said. In September, 15 months after his treatment, he was still in remission.

That's still a long way away. But the treatment Feldman received was just approved by the Food and Drug Administration under the brand name Yescarta, with a bracing price tag: $373,000 per patient. That doesn't include the costs of dealing Yecarta's side effects, which include life-threatening fevers triggered by the immune response the therapy creates that can mean weeks in the hospital, or other drugs patients must receive.

Read Forbes magazine article